- TheStreet.com•7 days ago
Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs.
- Business Wire•8 days ago
Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Puma Biotechnology, Inc. , a biopharmaceutical company, today announced that the U.S. Food and Drug Administration has scheduled the New Drug Application for neratinib for discussion by the Oncologic Drugs Advisory Committee on May 24, 2017.
- Business Wire•21 days ago
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that interim results from a Phase II clinical trial of Puma’s investigational drug PB272 were presented at the 2017 American Association for Cancer Research Annual Meeting that is currently taking place in Washington, D.C.
PBYI : Summary for Puma Biotechnology Inc - Yahoo Finance
Puma Biotechnology, Inc. (PBYI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||35.95 x 100|
|Ask||44.00 x 200|
|Day's Range||36.95 - 38.15|
|52 Week Range||19.74 - 73.27|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-4.50|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|